Business
Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology
Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of t...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, Nov. 16, 2017\n\n\n\nTORONTO and HOUSTON, TX, Nov. 16, 2017 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX \"MDNA\" and OTCQX \"MDNAF\") a clinical stage immuno-oncology company, announced that following the presentation of early results at the Congress for Neurosurgeons (Oct 9-11, 2017), additional clinical data from the on-going Phase 2b clinical trial of MDNA55 were presented at the 22nd Annual Meeting of the Society of Neuro-Oncology (\"SNO\") being held in San Francisco (November 15-19, 2017).\n\nDr. Krystof Bankiewicz, MD, PhD, Kinetics Foundation Chair in Translational Research and Professor in Residence of Neurological Surgery at the University of California San Francisco, provided an update on drug distribution and safety data from the first 15 patients treated to date in the MDNA55 Phase 2b clinical trial in adults with recurrent glioblastoma (\"rGBM\"), the most common and uniformly fatal form of brain cancer. \n\nMDNA55, is the Company's lead immunotherapeutic agent targeting the interleukin-4 receptor (\"IL-4R\") which is known to be over-expressed in brain tumors and the tumor micro-environment but not in healthy brain tissue.\n\n\"With MDNA55 and the techniques developed by the neurosurgeons participating in this study, we are entering a new era of high-volume drug delivery to tumors in the brain,\" states Dr. Bankiewicz. \"The greater the extent to which we can cover the tumor and the at-risk area immediately surrounding it, the more chance we have of changing the outcomes for the patients. These early data show that we are clearly making advances in the accuracy with which we can deliver MDNA55 into brain tumors and the extent of coverage achieved and we are optimistic for the benefits this might deliver to the patients.\" \n\nIn the study, MDNA55-05, investigators administer MDNA55 directly into brain t...